title: Effects of 5'-phosphate derivatives of 2-hexynyl adenosine and 2-phenylethynyl adenosine on responses of human platelets mediated by P2Y receptors.
abstract: Newly synthesized mono-, di-, and triphosphate of 2-alkynyl adenosines showed very different behavior in human platelet P2Y receptor models, according to the different alkynyl chains. In fact, 2-hexynyladenosine di- (5) and triphosphate (7) induced platelet shape change and aggregation and inhibited PGE(1)-induced increase in platelet cyclic AMP. On the contrary, the corresponding 2-phenylethynyladenosine di- (6) and triphosphate (8) did not induce platelet shape change or aggregation, but inhibited platelet aggregation induced by ADP.
authors.affiliation: Dipartimento di Scienze Chimiche, Università di Camerino, 62032 Camerino, Italy. gloria.cristalli@unicam.it
authors.forename: Gloria
authors.initials: G
authors.lastname: Cristalli
authors.forename: Gian Marco
authors.initials: GM
authors.lastname: Podda
authors.forename: Stefano
authors.initials: S
authors.lastname: Costanzi
authors.forename: Catia
authors.initials: C
authors.lastname: Lambertucci
authors.forename: Anna
authors.initials: A
authors.lastname: Lecchi
authors.forename: Sauro
authors.initials: S
authors.lastname: Vittori
authors.forename: Rosaria
authors.initials: R
authors.lastname: Volpini
authors.forename: Maddalena L
authors.initials: ML
authors.lastname: Zighetti
authors.forename: Marco
authors.initials: M
authors.lastname: Cattaneo
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives* / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D000480:Alkynes / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D001792:Blood Platelets / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D048430:Cell Shape / Q000187:drug effects; D000242:Cyclic AMP / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D006801:Humans; D066298:In Vitro Techniques; D008565:Membrane Proteins / Q000819:agonists / Q000187:drug effects* / Q000502:physiology; D010755:Organophosphates / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D058910:Purinergic P2 Receptor Agonists; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2 / Q000187:drug effects* / Q000502:physiology; D058472:Receptors, Purinergic P2Y1; D058925:Receptors, Purinergic P2Y12; D013329:Structure-Activity Relationship
chemical_list: D000480:Alkynes; D008565:Membrane Proteins; D010755:Organophosphates; C546382:P2RY1 protein, human; C548576:P2RY12 protein, human; D010975:Platelet Aggregation Inhibitors; D058910:Purinergic P2 Receptor Agonists; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2; D058472:Receptors, Purinergic P2Y1; D058925:Receptors, Purinergic P2Y12; C070493:2-hexynyladenosine; D000242:Cyclic AMP; D000241:Adenosine